Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Brii Biosciences Limited
腾盛博药生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2137)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE

This announcement is made by the board of directors (the "**Board**") of Brii Biosciences Limited (the "**Company**") on a voluntary basis.

The Board is pleased to announce the commercial launch of the amubarvimab/romlusevimab combination, a long-acting COVID-19 neutralizing antibody therapy, in China by TSB Therapeutics (Beijing) Co., Ltd. ("**TSB Therapeutics**"), a joint venture majority-owned by the Company. On July 7, 2022, the first commercial batch of the antibodies was released, marking an important milestone in the commercialization of the combination therapy.

The amubarvimab/romlusevimab combination was approved by the China's National Medical Products Administration in December 2021 for the treatment of adults and pediatric patients (age 12-17 weighing at least 40 kg) with mild and normal type of COVID-19 at high risk for progression to severe disease, including hospitalization or death. The indication of pediatric patients (age 12-17 weighing at least 40 kg) is under a conditional approval. In March 2022, the National Health Commission of China added the amubarvimab/romlusevimab combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition) (the "**Guidelines**") for the treatment of COVID-19.

On March 21, 2022, the National Healthcare Security Administration of China issued a notice to temporarily include the newly added drugs in the Guidelines into the reimbursement scope of the provincial health insurance fund. Since March 22, 2022, the Healthcare Security Administrations of various provinces and cities in China have successively implemented the instructions of the notice and included the amubarvimab/romlusevimab combination into the reimbursement scope of the local health insurance fund.

"We're proud to bring the first locally-discovered and approved COVID-19 treatment in China to patients in need with the support and guidance of relevant government authorities. The global Phase 3 clinical trial demonstrated clear patient benefit with 80% reduction of hospitalization and death. In addition, the live virus and pseudovirus testing data from multiple independent laboratories demonstrate that the amubarvimab/romlusevimab combination retains neutralizing activity against the live Omicron BA.2 subvariants prevalent in China and all previous variants of concern. These accomplishments reinforce our scientific expertise in infectious disease and underscore our mission to tackle the biggest public health challenges with breakthrough innovation and insight. Our employees are the heroes who have given their all to achieving this great honor," said Mr. Yongqing Luo, the President and General Manager of Greater China of the Company and the Chief Executive Officer of TSB Therapeutics. "Our first priority will be to coordinate with our commercial partners to manage the distribution of the amubarvimab/romlusevimab combination in China to patients with the highest unmet need for our novel treatment, to protect people's lives."

In 2021, the Company donated nearly 3,000 doses of the amubarvimab/romlusevimab combination for emergency use in 22 hospitals in 21 cities in China as part of its commitment to ensure humanitarian access and to help curbing the outbreaks of the delta variants.

"Despite the progress being made with vaccines, the pandemic continues to affect the health of communities in China, and we believe that, based on the clinical data generated in partnership with top-tier global research institutions, the amubarvimab/romlusevimab combination treatment has the potential to bring significant clinical benefit to patients in need and support communities under threat of SARS-CoV-2 infection," said Dr. Qing Zhu, Ph.D., the Senior Vice President, Head of Biopharmaceutical Research of the Company. "When we made the decision to invest significant resources and expertise in the fight against COVID-19, we knew this would be a considerable undertaking and we must play our part. We could not have made it to this point of bringing our much-needed medicine to patients throughout China without the support of our world-class partners and we look forward to continuing to work with stakeholders across the industry to enable the timely distribution of the combination therapy to healthcare providers and patients."

Cautionary Statement: Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. When in doubt, shareholders of the Company and potential investors are advised to seek advice from professional or financial advisers.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, July 7, 2022

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Mr. Yongqing Luo as executive directors; Mr. Robert Taylor Nelsen and Dr. Axel Bouchon as non-executive directors; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui and Mr. Gregg Huber Alton as independent non-executive directors.